Search / 141 results found

from
to
  • Updated

ATLANTA, July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that, after a review of safety, tolerability and pharmacokinetic data from the Company's Phase 1 clinical trial of IkT-148009 in healthy volunteers, the United States Food and Drug Administration (FDA) has given the Company clearance to begin a Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's patients.

  • Updated

The obesity epidemic in the U.S. is a major health issue, and it’s getting worse. The current national adult obesity rate is 29.7%, but almost half of adults are projected to be obese, not just overweight, by 2030, according to Harvard researchers estimates published in December 2019 in the New England Journal of Medicine. While […]

The obesity epidemic in the U.S. is a major health issue, and it’s getting worse. The current national adult obesity rate is 29.7%, but almost half of adults are projected to be obese, not just overweight, by 2030, according to Harvard researchers estimates published in December 2019 in the New England Journal of Medicine. While […]

The obesity epidemic in the U.S. is a major health issue, and it’s getting worse. The current national adult obesity rate is 29.7%, but almost half of adults are projected to be obese, not just overweight, by 2030, according to Harvard researchers estimates published in December 2019 in the New England Journal of Medicine. While […]

The obesity epidemic in the U.S. is a major health issue, and it’s getting worse. The current national adult obesity rate is 29.7%, but almost half of adults are projected to be obese, not just overweight, by 2030, according to Harvard researchers estimates published in December 2019 in the New England Journal of Medicine. While […]

The obesity epidemic in the U.S. is a major health issue, and it’s getting worse. The current national adult obesity rate is 29.7%, but almost half of adults are projected to be obese, not just overweight, by 2030, according to Harvard researchers estimates published in December 2019 in the New England Journal of Medicine. While […]

  • Updated

The obesity epidemic in the U.S. is a major health issue, and it’s getting worse. The current national adult obesity rate is 29.7%, but almost half of adults are projected to be obese, not just overweight, by 2030, according to Harvard researchers estimates published in December 2019 in the New England Journal of Medicine. While […]

  • Updated

The obesity epidemic in the U.S. is a major health issue, and it’s getting worse. The current national adult obesity rate is 29.7%, but almost half of adults are projected to be obese, not just overweight, by 2030, according to Harvard researchers estimates published in December 2019 in the New England Journal of Medicine. While […]

  • Updated

DURHAM, N.C., July 22, 2021 /PRNewswire/ -- Inhalon Biopharma, Inc., a clinical-stage immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating a variety of acute respiratory infections, today announced it is partnering with Celltrion, Inc. to develop IN-006, an inhaled form of regdanvimab, for treating patients with COVID-19.

  • Updated

ATLANTA, July 22, 2021 /PRNewswire/ -- VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company focused on saving lives, alleviating suffering, and improving the health economics of care, today announced that they voluntarily issued a correction to Software version 2.2.3 for GENOSYL® DS devices, which is classified as a Class 1 recall. VERO Biotech worked with the FDA to issue the recall communication and take action to correct the issue. As of May 14, 2021, all GENOSYL® DS devices affected by the recall were updated to the latest software version in the field. This correction did not require any removals of GENOSYL® DS devices. VERO continues to work with the FDA to close the recall.